---
title: Feasibility of Visual Field Testing With a Virtual Reality Headset
nct_id: NCT03748654
overall_status: SUSPENDED
phase: NA
sponsor: Brennan Eadie
study_type: INTERVENTIONAL
primary_condition: Glaucoma
countries: Canada
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03748654.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03748654"
ct_last_update_post_date: 2021-08-02
last_seen_at: "2026-05-12T06:21:21.214Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Feasibility of Visual Field Testing With a Virtual Reality Headset

**NCT ID:** [NCT03748654](https://clinicaltrials.gov/study/NCT03748654)

## Key Facts

- **Status:** SUSPENDED
- **Why Stopped:** COVID-19
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 30
- **Lead Sponsor:** Brennan Eadie
- **Conditions:** Glaucoma
- **Start Date:** 2022-01-01
- **Completion Date:** 2023-07-01
- **CT.gov Last Update:** 2021-08-02

## Brief Summary

This study aim to determine the feasibility of using a virtual reality (VR) headset (HTC Vive) to test the visual field. The VR headset test will be compared to a conventional visual field test, using the Humphrey Field Analyzer. The investigators will include 10 healthy patients without visual field defect, 10 patients with early glaucomatous visual field defect, and 10 patients with advanced visual field defect. Each patient will perform the conventional test twice and the VR headset test 4 times, divided in 3 visits within a 2 month period. The results of the tests (sensitivity thresholds) will be compared. The investigators hypothesize that the results of the conventional and VR tests will be similar.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Previous visual field test with Humphrey Field Analyzer indicating normal field, early glaucomatous field damage, or advanced glaucomatous field damage, according to Canadian Glaucoma Society Guidelines.
* Ability to understand and consent to the study.

Exclusion Criteria:

* Presence of non-glaucomatous pathology that could influence the visual field test, such as media opacities.
* Previous intraocular surgery less than 6 months from inclusion.
* Difficulty to execute a reliable visual field test.
* Potential contra-indications to use of virtual reality headset, including: anxiety disorder, pregnancy, seizure disorder, cardiac pacemaker or other implantable device, severe vertigo or balance disturbance.
```

## Arms

- **Single Arm** (EXPERIMENTAL) — Patients will perform visual field testing with the Humphrey Field Analyzer and with the Virtual Reality Headset

## Interventions

- **Visual Field Testing** (DIAGNOSTIC_TEST) — Visual field test using the protocol 24-2 Threshold Test

## Primary Outcomes

- **Visual field differential light sensitivity threshold** _(time frame: Three weeks)_ — Comparison of differential light sensitivity threshold estimated with the Humphrey Field Analyzer and the Virtual Reality headset

## Secondary Outcomes

- **Reproducibility of sensitivity values** _(time frame: Three weeks)_

## Locations (1)

- Victoria General Hopsital - Nova Scotia Health Authority, Halifax, Nova Scotia, Canada

## Recent Field Changes (last 30 days)

- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.whyStopped` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.victoria general hopsital - nova scotia health authority|halifax|nova scotia|canada` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03748654.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03748654*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*